Psychiatric Times

JULY 7, 2025

MindMed initiated a phase 3 study of MM120 for major depressive disorder, with results expected in the second half of 2026. Cybin partnered with Osmind to advance psychiatry programs, focusing on CYB003 and CYB004 for major depressive and generalized anxiety disorders.

Pharmaceuticals

Mad in America

MARCH 19, 2025

In one of your articles on neoliberalism and psychological ethics, you discuss the striking increase in social anxiety diagnoses over the past 30 years. Take multiple personality disorder , for example. At one point, there was even a bar in New York specifically for people who identified as having multiple personalities.

Poverty and mental health

Mad in America

SEPTEMBER 13, 2024

Everything that I had been told was part of an elaborate, profiteering form of mass human control by psychiatrists, pharmaceutical companies, and governments. In my desperation and loneliness, I had been the perfect psychiatric victim. Only a little bit,” they nonchalantly responded.

Trauma and the brain

Mad in America

NOVEMBER 27, 2024

The mental health industry, including therapists, pharmaceutical companies, and even heads of departments and trauma experts, have a vested interest in diagnosing as many individuals as possible. It is a serious disorder, reflecting the deep psychological scars left by genuine trauma.

Resilience and coping